Implication of substance P neuronal system in the amygdala as a possible mechanism for hypergravity-induced motion sickness

Brain Res. 2012 Jan 30:1435:91-8. doi: 10.1016/j.brainres.2011.11.047. Epub 2011 Dec 1.

Abstract

We previously reported that motion sickness was prevented in rats with amygdala lesion and that provocative motion stimuli increased the number of Fos-positive neurons in the amygdala, suggesting that the amygdala is one of the neural substrates involved in the development of motion sickness. NK-1 receptors in the brain stem and amygdala are thought to play an important role in emesis and affective disorders, respectively. In the present study, to elucidate a role of substance P neuronal system and NK-1 receptors in the brain stem and amygdala in the development of motion sickness, we measured changes in gene expression of NK-1 receptors and preprotachykinin, a precursor of substance P, using quantitative real-time PCR methods in solitary tract nucleus and amygdala in rats after provocative motion stimuli induced by 2G hypergravity load. Effects of systemic administration of CP-99,994, an antagonist for NK-1 receptors, on hypergravity-induced motion sickness were also examined using pica behavior, eating non-nutritive substances such as kaolin, as an index of motion sickness in rats. Hypergravity-induced motion sickness was inhibited by CP-99,994 with a dose-dependent and enantioselective manner. Preprotachykinin mRNA expression was increased in basolateral nucleus of amygdala and solitary tract nucleus after hypergravity load for 3h, whereas NK-1 receptor mRNA expression was not changed by hypergravity in amygdala and solitary tract nucleus. Present results suggest that 2G hypergravity load activated the substance P neuronal system in amygdala as well as in the brain stem and this activation would be related to the development of motion sickness.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amygdala / metabolism*
  • Amygdala / pathology
  • Analysis of Variance
  • Animals
  • Brain Stem / metabolism
  • Brain Stem / pathology
  • Disease Models, Animal
  • Eating / drug effects
  • Eating / physiology
  • Gene Expression Regulation / drug effects
  • Gene Expression Regulation / physiology*
  • Hypergravity / adverse effects
  • Kaolin / administration & dosage
  • Male
  • Motion Sickness / drug therapy
  • Motion Sickness / etiology
  • Motion Sickness / pathology*
  • Neurokinin-1 Receptor Antagonists
  • Piperidines / pharmacology
  • Piperidines / therapeutic use
  • Protein Precursors / genetics
  • Protein Precursors / metabolism*
  • RNA, Messenger / metabolism
  • Rats
  • Rats, Wistar
  • Receptors, Neurokinin-1 / genetics
  • Receptors, Neurokinin-1 / metabolism*
  • Tachykinins / genetics
  • Tachykinins / metabolism*
  • Time Factors

Substances

  • Neurokinin-1 Receptor Antagonists
  • Piperidines
  • Protein Precursors
  • RNA, Messenger
  • Receptors, Neurokinin-1
  • Tachykinins
  • preprotachykinin
  • 3-(2-methoxybenzylamino)-2-phenylpiperidine
  • Kaolin